A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Merck Sharp & Dohme LLC
Beijing Biotech
Parabilis Medicines, Inc.
Pfizer
Aulos Bioscience, Inc.
Arsenal Biosciences, Inc.
Hoffmann-La Roche
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Tasca Therapeutics
Essen Biotech
Essen Biotech
Kidney Cancer Research Bureau
Second Life Therapeutics
Ocellaris Pharma, Inc.
Tyra Biosciences, Inc
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
GI Innovation, Inc.
Incyte Corporation
Sensei Biotherapeutics, Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Kymab Limited
CHU de Quebec-Universite Laval
Indiana University
PureTech
GI Innovation, Inc.
Salubris Biotherapeutics Inc
Vector Vitale LLC
Altor BioScience
Hookipa Biotech GmbH
Medikine, Inc.
NextCure, Inc.
Processa Pharmaceuticals
Fred Hutchinson Cancer Center
Nektar Therapeutics
Nektar Therapeutics
Institut Bergonié
University of California, San Francisco
Incyte Corporation
NKGen Biotech, Inc.
Dana-Farber Cancer Institute
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Icahn School of Medicine at Mount Sinai